Literature DB >> 10894872

Occult ovarian tumors in women with BRCA1 or BRCA2 mutations undergoing prophylactic oophorectomy.

K H Lu1, J E Garber, D W Cramer, W R Welch, J Niloff, D Schrag, R S Berkowitz, M G Muto.   

Abstract

PURPOSE: To review the findings at prophylactic oophorectomy of a series of women who presented to a familial breast and ovarian cancer clinic.
MATERIALS AND METHODS: Data from medical charts, operative notes, and pathology reports were collected on women who had undergone prophylactic oophorectomies because of the elevated risk of ovarian cancer. Because only a subset of patients underwent BRCA1 and BRCA2 testing, each patient's risk of hereditary predisposition was calculated using the Berry-Parmigiani model and family history data.
RESULTS: From June 1989 to December 1998, 50 women seen at our clinic underwent prophylactic oophorectomy, 33 of whom had a calculated risk of carrying a germline BRCA1 or BRCA2 mutation greater than 25%. Among this group, four incidental tumors were found (four of 33, or 12%); one tumor was noted at the time of surgery and three were noted only in the final pathology. Two patients had microscopic, poorly differentiated serous adenocarcinomas in multiple sites on both ovaries. A third patient had a bilateral serous borderline tumor with micropapillary features. The fourth patient had a microscopic serous borderline ovarian tumor. All four patients had germline BRCA1 or BRCA2 mutations, and three had unremarkable transvaginal ultrasonography examinations within 6 months before prophylactic surgery.
CONCLUSION: Foci of malignant tumor are not uncommon in prophylactic oophorectomies performed in women at very high risk for ovarian cancer and may not be detected on ultrasonograms. Surgeons should have a high suspicion of finding cancer in these women at the time of prophylactic surgery, and careful pathologic assessment of the specimens should be conducted.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10894872     DOI: 10.1200/JCO.2000.18.14.2728

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  28 in total

Review 1.  The clinical management of BRCA1 and BRCA2 mutation carriers.

Authors:  Anthony P Gulati; Susan M Domchek
Journal:  Curr Oncol Rep       Date:  2008-01       Impact factor: 5.075

2.  Microscopic and early-stage ovarian cancers in BRCA1/2 mutation carriers: building a model for early BRCA-associated tumorigenesis.

Authors:  Melinda S Yates; Larissa A Meyer; Michael T Deavers; Molly S Daniels; Elizabeth R Keeler; Samuel C Mok; David M Gershenson; Karen H Lu
Journal:  Cancer Prev Res (Phila)       Date:  2011-01-28

3.  Peritoneal washing cytology in patients with BRCA1 or BRCA2 mutations undergoing risk-reducing salpingo-oophorectomies: a 10-year experience and reappraisal of its clinical utility.

Authors:  G Landon; J Stewart; M Deavers; K Lu; N Sneige
Journal:  Gynecol Oncol       Date:  2012-03-13       Impact factor: 5.482

Review 4.  Genetic risk and gynecologic cancers.

Authors:  Laura L Holman; Karen H Lu
Journal:  Hematol Oncol Clin North Am       Date:  2012-02       Impact factor: 3.722

5.  Acceptability of prophylactic salpingectomy with delayed oophorectomy as risk-reducing surgery among BRCA mutation carriers.

Authors:  Laura L Holman; Sue Friedman; Molly S Daniels; Charlotte C Sun; Karen H Lu
Journal:  Gynecol Oncol       Date:  2014-02-28       Impact factor: 5.482

Review 6.  New insights into the pathogenesis of serous ovarian cancer and its clinical impact.

Authors:  Keren Levanon; Christopher Crum; Ronny Drapkin
Journal:  J Clin Oncol       Date:  2008-10-14       Impact factor: 44.544

7.  Perceptions of risk and reward in BRCA1 and BRCA2 mutation carriers choosing salpingectomy for ovarian cancer prevention.

Authors:  Talayeh S Ghezelayagh; Lauren E Stewart; Barbara M Norquist; Deborah J Bowen; Vivian Yu; Kathy J Agnew; Kathryn P Pennington; Elizabeth M Swisher
Journal:  Fam Cancer       Date:  2020-02-24       Impact factor: 2.375

8.  A prospective study of risk-reducing salpingo-oophorectomy and longitudinal CA-125 screening among women at increased genetic risk of ovarian cancer: design and baseline characteristics: a Gynecologic Oncology Group study.

Authors:  Mark H Greene; Marion Piedmonte; Dave Alberts; Mitchell Gail; Martee Hensley; Zoe Miner; Phuong L Mai; Jennifer Loud; Gustavo Rodriguez; Jack Basil; John Boggess; Peter E Schwartz; Joseph L Kelley; Katie E Wakeley; Lori Minasian; Stephen Skates
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-03       Impact factor: 4.254

9.  Pilot Clinical Evaluation of a Confocal Microlaparoscope for Ovarian Cancer Detection.

Authors:  Matthew D Risi; Andrew R Rouse; Setsuko K Chambers; Kenneth D Hatch; Wenxin Zheng; Arthur F Gmitro
Journal:  Int J Gynecol Cancer       Date:  2016-02       Impact factor: 3.437

10.  The preclinical natural history of serous ovarian cancer: defining the target for early detection.

Authors:  Patrick O Brown; Chana Palmer
Journal:  PLoS Med       Date:  2009-07-28       Impact factor: 11.069

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.